Orbimed Advisors LLC Cin Cor Pharma, Inc. Call Options Transaction History

Orbimed Advisors LLC

  • $4.24 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding CINC

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CinCor Pharma, Inc.

CINC Quotes by TradingView
  • Ticker CINC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,764,300
  • Description
  • CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...
More about CINC
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email